Dysregulation and functional roles of miR-183-96-182 cluster in cancer cell proliferation, invasion and metastasis

Ma, Yi; Liang, Ajuan; Fan, Yu-Ping; Huang, Yiran; Zhao, Xiaoming; Sun, Yun; Chen, Xiang-Feng

doi:10.18632/oncotarget.8715

Cited by 72 publications

(70 citation statements)

References 178 publications

(173 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our results, hsa-mir-1269a has log2FC value consistently larger than 2.20 in each of its eight associated cancer types (average log2FC = 5.18), with the average frequency of affected patients greater than 64.58% for a strict fold change requirement (FC > 5 for each patient). Other members of the 21 key SDEmiRNAs (Table 3) include hsa-mir-183 and hsa-mir-96, belonging to the mir-183-96-182 cluster, which functions to induce cell proliferation and cancer development [46]. Notably, unlike the other two miRNAs from the same cluster, hsa-mir-182 only shows significant differential expression but not high patient frequencies.…”

Section: Resultsmentioning

confidence: 99%

Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis

Dingerdissen

Gupta

et al. 2018

Computers in Biology and Medicine

View full text Add to dashboard Cite

microRNAs (miRNAs) functioning in gene silencing have been associated with cancer progression. However, common abnormal miRNA expression patterns and their potential roles in cancer have not yet been evaluated. To account for individual differences between patients, we retrieved miRNA sequencing data for 575 patients with both tumor and adjacent nontumorous tissues from 14 cancer types from The Cancer Genome Atlas (TCGA). We then performed differential expression analysis using DESeq2 and edgeR. Results showed that cancer types can be grouped based on the distribution of miRNAs with different expression patterns between tumor and non-tumor samples. We found 81 significantly differentially expressed miRNAs (SDEmiRNAs) in a single cancer. We also found 21 key SDEmiRNAs (nine over-expressed and 12 under-expressed) associated with at least eight cancers each and enriched in more than 60% of patients per cancer, including four newly identified SDEmiRNAs (hsa-mir-4746, hsa-mir-3648, hsa-mir-3687, and hsa-mir-1269a). The downstream effects of these 21 SDEmiRNAs on cellular function were evaluated through enrichment and pathway analysis of 7,186 protein-coding gene targets mined from literature reports of differential expression of miRNAs in cancer. This analysis enables identification of SDEmiRNA functional similarity in cell proliferation control across a wide range of cancers, and assembly of common regulatory networks over cancer-related pathways. These findings were validated by construction of a regulatory network in the PI3K pathway. This study provides evidence for the value of further analysis of SDEmiRNAs as potential biomarkers and therapeutic targets for cancer diagnosis and treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis

Dingerdissen

Gupta

et al. 2018

Computers in Biology and Medicine

View full text Add to dashboard Cite

show abstract

“…Other members of the 21 key SDEmiRNAs (Table 3) include hsa-mir-183 and hsa-mir-96, which belong to the mir-183-96-182 cluster, which functions to induce cell proliferation and cancer development [39]. Notably, unlike the other two miRNAs from the same cluster, hsa-mir-182 only shows significantly differential expression but not high patient frequencies.…”

Section: Key Sdemirnas With At Least 60% Patient Frequencies Were Conmentioning

confidence: 99%

Identification of Key Differentially Expressed MicroRNAs in Cancer Patients Through Pan-cancer Analysis

Dingerdissen

Gupta

et al. 2018

Preprint

View full text Add to dashboard Cite

A number of microRNAs (miRNAs) functioning in gene silencing have been associated with cancer progression. However, common expression patterns of abnormally expressed miRNAs and their potential roles in multiple cancer types have not yet been evaluated. To minimize the difference of patients, we collected miRNA sequencing data of 575 patients with tumor and adjacent non-tumorous tissues from 14 cancer types from The Cancer Genome Atlas (TCGA), and performed differential expression analysis using DESeq2 and edgeR. The results showed that cancer types can be grouped based on the distribution of miRNAs with different expression patterns. We found 81 significantly differentially expressed miRNAs (SDEmiRNAs) unique to one of the 14 cancers may affect patient survival rate, and 21 key SDEmiRNAs (nine overexpressed and 12 under-expressed) associated with at least eight cancers and enriched in more than 60% of patients per cancer, including four newly identified SDEmiRNAs (hsa-mir-4746, hsa-mir-3648, hsa-mir-3687, and hsa-mir-1269a). The downstream effect of these 21SDEmiRNAs on cellular functions was evaluated through enrichment and pathway analysis of 7,186 protein-coding gene targets from literature mining with known differential expression profiles in cancers. It enables identification of their functional similarity in cell proliferation control across a wide range of cancers and to build common regulatory networks over cancer-related pathways. This is validated by construction of a regulatory network in PI3K pathway. This study provides evidence of the value of further analysis on SDEmiRNAs as potential biomarkers and therapeutic targets for cancer diagnosis and treatment.

show abstract

“…miR-96 is located at human chromosome locus 7q32.2, and the amplification of human chromosome 7 is important in lung cancer (19), hepatocellular carcinoma (20), prostate cancer (21), gastric cancer (22), esophageal cancer (23), breast cancer (24) and other types of tumor (9-13). miR-96 is highly expressed in those types of cancer and has been considered to be an oncogenic miRNA (25). Han et al (9) applied the gene expression microarray to validate that miR-96 expression was upregulated in bladder cancer tissue.…”

Section: Discussionmentioning

confidence: 99%

Anticancer effect of miR-96 inhibitor in bladder cancer cell lines

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. The present study aimed to investigate the role of microRNA-96 (miR-96) in the proliferation, invasion and apoptosis of bladder cancer cell lines, and the associated mechanisms. The expression of miR-96 and human ether-à-go-go-related (HERG1) potassium channel in the normal uroepithelium SV-HUC-1 cell line, and bladder cancer T24 and 5637 cell lines were examined using reverse transcription-polymerase chain reaction or/and western blotting. Transfection with miR-96 inhibitor or scrambled control (SC) was used to study the biological activities of miR-96 in bladder cancer cell lines. MTT, flow cytometric and Transwell assays were applied to detect cell viability, apoptosis and invasion, respectively. A dual-luciferase reporter assay was applied to determine the association between miR-96 and HERG1 expression. As demonstrated, miR-96 was highly expressed in the two bladder cancer cell lines, particularly in T24 cells. Following transfection with miR-96 inhibitor, miR-96 expression was significantly reduced in the T24 cell line, compared with SC. The miR-96 inhibitor suppressed cell proliferation and invasion, promoted apoptosis and arrested the cell cycle at the G 1 phase. Consistently, HERG1 was also highly expressed in the two bladder cancer cell lines at the mRNA and protein level, but not in the normal uroepithelium cell line. The miR-96 inhibitor also significantly decreased HERG1 expression compared with SC. The results of the dual-luciferase reporter assay indicated that miR-96 directly targeted wild-type HERG1. In conclusion, miR-96 inhibitor exhibited anticancer effects on bladder cancer cells by inhibiting proliferation and invasion of cells, and promoting their apoptosis. HERG1 was an important target of miR-96. These results provided experimental evidence supporting miR-96 as a therapeutic target for patients with bladder cancer.

show abstract

Dysregulation and functional roles of miR-183-96-182 cluster in cancer cell proliferation, invasion and metastasis

Cited by 72 publications

References 178 publications

Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis

Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis

Identification of Key Differentially Expressed MicroRNAs in Cancer Patients Through Pan-cancer Analysis

Anticancer effect of miR-96 inhibitor in bladder cancer cell lines

Contact Info

Product

Resources

About